Answers are grounded in this paper and cite their sources.
The evaluation shows wound healing enhancement by butanol and ethyl acetate fractions in rats, indicating potential therapeutic applications.
Cleistopholis staudtii is a medicinal plant traditionally used in Africa for wound management, but its scientific validation remains limited. This study evaluated the wound-healing efficacy, phytochemical composition, and safety profile of its ethanol extract and solvent fractions. Leaves were macerated in ethanol to obtain a crude extract (19.1% yield), which was fractionated into n-hexane (HF), ethyl acetate (EAF), and n-butanol (BF) fractions, with EAF showing the highest yield (30.4%). Phytochemical analysis revealed abundant flavonoids (8.6%) and phenolics, particularly in EAF and BF. Acute toxicity testing in mice established an LD₅₀ exceeding 5000 mg/kg, indicating high safety. In excision wound models (50 rats), topical application of 10% BF and 10% EAF formulations significantly increased wound closure, achieving near-complete healing by Day 18 (comparable to cicatrin powder, p < 0.05), while petroleum jelly controls showed minimal improvement. LC-MS analysis identified key bioactive compounds, including kaempferol glycosides (antioxidant), eugenol (antimicrobial), and salicin (anti-inflammatory), which likely synergistically promoted tissue regeneration through anti-inflammatory, antimicrobial, and collagen-modulating mechanisms. These findings scientifically validate the traditional use of C. staudtii and highlight its 10% butanol and ethyl acetate fractions as promising candidates for development into standardized wound-healing agents.
No takes yet. Share an insight, caveat, or question.
Onwuzuligbo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: